Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;12(11):6992-7001.
doi: 10.21037/jtd-20-1472.

Changing paradigm in advanced and metastatic non-small cell lung cancer

Dipesh Uprety  1 , Kaushal Parikh  2 , Anita Sawkar  3 , Anastasios Dimou  1 , Konstantinos Leventakos  1
Affiliations
Review

Changing paradigm in advanced and metastatic non-small cell lung cancer

Dipesh Uprety et al. J Thorac Dis. 2020 Nov.

Abstract

Lung cancer is the most common cancer worldwide. Approximately 18% of all deaths related to cancer are associated with lung cancer. Management of non-small cell lung cancer (NSCLC) has been changing rapidly in last few years. For patients with unresectable non-metastatic disease, maintenance durvalumab is now given after offering chemo-radiation concurrently based on the result from the PACIFIC trial. Management of metastatic disease greatly depends on the status of sensitizing driver mutation and PD-L1 level of the tumor cells. In this review article, we will summarize the outcome of various clinical trials and will provide the most up-to-date information on the management of patients with advanced and metastatic NSCLC.

Keywords: Advanced; lung cancer; metastatic; non-small cell lung cancer (NSCLC); stage III; stage IV.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-1472). The series “Contemporary Practice in Thoracic Neoplasm Diagnosis, Evaluation and Treatment” was commissioned by the editorial office without any funding or sponsorship. Dr. KP reports personal fees from Astra-Zeneca. Dr. KL reports honoraria from Onc Live and Takeda. Dr. AD reports personal fees from Roche/Genentech, personal fees from OncLive. The other authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Treatment algorithm for patients with advanced or metastatic NSCLC. NSCLC, non-small cell lung cancer.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94. 10.1016/S0025-6196(11)60735-0 - DOI - PMC - PubMed
    1. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60. 10.1056/NEJMoa031644 - DOI - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res 2019;11:943-53. 10.2147/CMAR.S187317 - DOI - PMC - PubMed